

APR. 22. 2004 4:26PM

RECEIVED
CENTRAL FAX CENTER

APR 22 2004

NO. 9046 P. 1/7

OFFICIAL

Shook,
Hardy &
Bacon LLP
www.shb.com

TO
EXAMINER MARJORIE A. MORAN
US PATENT AND TRADEMARK OFFICE
ART UNIT 1631

PHONE

FAX
1-703-872-9306

Jean M. Dickman

2555 Grand Blvd.
Kansas City
Missouri 64108-2613
816.474.6550
816.421.5547 Fax
jdickman@shb.com

FROM
JEAN M. DICKMAN

IT #
2463

MATTER #
CRNC.83071

DATE
APRIL 22, 2004

7 Pages Transmitted
Original Document

If you experience any problems, please call 816.474.6550 extension _____.

COMMENTS:

fax

Confidentiality Notice: The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual(s) or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for return of the original documents to us.

Geneva
Houston
Kansas City
London
Miami
New Orleans
Orange County
Overland Park
San Francisco
Tampa
Washington, D.C.

APR. 22. 2004 4:26PM

NO. 9046 P. 2/7

RECEIVED
CENTRAL FAX CENTER

APR 22 2004

Shook,
Hardy &
Bacon LLP
www.shb.com

April 22, 2004

VIA FAX NO. 703-872-9306

OFFICIAL

2555 Grand Blvd.
Kansas City
Missouri 64108-2813
816.474.8550
816.421.5547 Fax


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: Applicant(s): Mark a. Hoffman et al.
Serial No. 09/981,248; Filed October 16, 2001
Title: Computer System for Providing Information About the Risk of an Atypical
Clinical Event Based Upon Genetic Information
Attorney Docket No. CRNC.83071
Examiner: Moran, Marjorie A.; Art Unit: 1631
Customer No. 05251

Dear Sir:

Enclosed is a revised Response to Restriction Requirement in the above patent application. We inadvertently mailed a Response on April 15, 2004, without the complete listing of claims of the group we have elected for further prosecution. Please substitute this Response dated April 22, 2004, for the response filed on April 15, 2004.

Sincerely,



Jean M. Dickman

JMG:sls
Enclosure

Geneva
Houston
Kansas City
London
Miami
New Orleans
Orange County
Overland Park
San Francisco
Tampa
Washington, D.C.

1425102v1

APR. 22. 2004 4:27PM

RECEIVED
CENTRAL FAX CENTER

NO. 9046 P. 3/7

OFFICIAL

APR 22 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant(s): Mark A. Hoffman and
David P. McCallie, Jr.

) Attorney Docket No. CRNC.83071
)

Serial No. 09/981,248

) Examiner: MORAN, Marjorie A.
)

Filed: October 16, 2001

) Art Unit: 1631
)

Title: Computer System for Providing
Information About the Risk of an Atypical
Clinical Event Based Upon Genetic
Information

CERTIFICATE OF TRANSMISSION 37 C.F.R. 1.8
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax. No. 703-872-9306, on:
<u>4-22-04</u> <u>Sandra Sutton</u>
Date Sandra Sutton

REVISED RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Office Action mailed March 23, 2004, please amend the above-identified application as follows:

Claims

Group I, claims 1-17, 31-47, and 61-77 (canceled).

Group II, claims 18-24, 48-54, and 78-84 (canceled).

Group III, claims 25-30, 55-60, and 85-90, are elected as follows:

25. (original): A method in a computer system for processing hereditary data related to the use of clinical agents by a person, comprising the steps of:

1420365v1

Serial No. 09/981,248

Filed: 10/16/2001

receiving a genetic test result value for the person;

determining if the genetic test result value is a polymorphism value associated with an atypical clinical event, and if so, accessing a list of risk-associated agents; and

outputting an interpretation of the genetic test result value and the list of risk-associated agents.

26. (original): The method of claim 25, further comprising the step of determining if the person has been exposed to an agent on the list of risk-associated agents.

27. (original): The method of claim 26, wherein the step of determining if the person has been exposed includes accessing an electronic medical record of the person.

28. (original): The method of claim 27, wherein the electronic medical record is stored within a comprehensive healthcare system.

29. (original): The method of claim 26, further comprising the step of initiating a clinical action if the person has been exposed to an agent on the list of risk-associated agents.

30. (original): The method of claim 29, wherein the clinical action is generating an electronic message to inform a clinician to no longer administer the agent.

55. (original): A computer system for processing hereditary data related to the use of clinical agents by a person, comprising the steps of:

a receiving component that receives a genetic test result value for the person;

a first determining component that determines if the genetic test result value is a polymorphism value associated with an atypical clinical event;

Serial No. 09/981,248
Filed: 10/16/2001

an accessing component that accesses a list of risk-associated agents if the determining component determines that a genetic test result value is polymorphism value associated with an atypical event; and

an outputting component that outputs an interpretation of the genetic test result value and the list of risk-associated agents.

56. (original): The computer system of claim 55, further comprising a second determining that determines if the person has been exposed to an agent on the list of risk-associated agents.

57. (original): The computer system of claim 56, wherein the second determining component determines if the person has been exposed includes an accessing component that accesses an electronic medical record of the person.

58. (original): The computer system of claim 57, wherein the electronic medical record is stored within a comprehensive healthcare system.

59. (original): The computer system of claim 56, further comprising an initiating component that initiates a clinical action if the person has been exposed to an agent on the list of risk-associated agents.

60. (original): The computer system of claim 59, wherein the clinical action is generating an electronic message to inform a clinician to no longer administer the agent.

85. (original): A computer-readable medium containing instructions for processing hereditary data related to the use of clinical agents by a person, comprising the steps of:

receiving a genetic test result value for the person;

Serial No. 09/981,248

Filed: 10/16/2001

determining if the genetic test result value is a polymorphism value associated with an atypical clinical event, and if so, accessing a list of risk-associated agents; and

outputting an interpretation of the genetic test result value and the list of risk-associated agents.

86. (original): The computer-readable medium of claim 85, further comprising the step of determining if the person has been exposed to an agent on the list of risk-associated agents.

87. (original): The computer-readable medium of claim 86, wherein the step of determining if the person has been exposed includes accessing an electronic medical record of the person.

88. (original): The computer-readable medium of claim 87, wherein the electronic medical record is stored within a comprehensive healthcare system.

89. (original): The computer-readable medium of claim 86, further comprising the step of initiating a clinical action if the person has been exposed to an agent on the list of risk-associated agents.

90. (original): The computer-readable medium of claim 89, wherein the clinical action is generating an electronic message to inform a clinician to no longer administer the agent.

Remarks

Applicants hereby elect for further prosecution claims 25-30, 55-60, and 85-90, which are the claims of Group III, according to the Examiner's classification. Applicants have canceled the non-elected claims (Group I, claims 1-17, 31-47, and 61-77, and Group II, claims 18-24, 48-54, and 78-84), although Applicants reserve the right to file continuation or divisional


Serial No. 09/981,248
Filed: 10/16/2001

applications directed to the subject matter of the non-elected claims prior to the issuance of a patent on those claims elected for further prosecution at this time.

It is believed that no fee is due. However, the Commissioner is hereby authorized to charge any amount required to Account No. 19-2112. A duplicate copy of this sheet is enclosed.

An action on the merits is solicited.

Respectfully submitted,



Jean M. Dickman
Reg. No. 48,538

JMD/sls

SHOOK, HARDY & BACON L.L.P.
2555 Grand Blvd.
Kansas City, Missouri 64108-2613
816/474-6550